Search results for "TUMOR"

showing 10 items of 6365 documents

Clear cell variant of calcifying epithelial odontogenic tumor: case report with immunohistochemical findings

2015

Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic neoplasm, locally aggressive, characterized by sheets and nests of polyhedral epithelial cells exhibiting eosinophilic cytoplasm or less often clear cytoplasm. Additional features include nuclear pleomorphism without mitotic activity, concentric calcifications, and deposits of amyloid. Herein, we present an additional example of clear cell variant of CEOT occurring in a 25-year-old female. Microscopically, the tumor consisted on proliferation of epithelial cells with eosinophilic, clear vacuolated cytoplasm interspersed with focal areas of amyloid deposition. Tumor cells were immunopositive for AE1/AE3, CK14, CK19, …

medicine.medical_specialtyPathologyOral Medicine and Pathologybusiness.industryCase ReportOdontologíamedicine.disease:CIENCIAS MÉDICAS [UNESCO]Benign Odontogenic NeoplasmCiencias de la saludCalcifying epithelial odontogenic tumorstomatognathic diseasesCytoplasmEosinophilicUNESCO::CIENCIAS MÉDICASMedicineImmunohistochemistryHistopathologybusinessGeneral DentistryMitosisClear cell
researchProduct

Occurrence of Contralateral Lymph Neck Node Metastasis in Patients with Squamous Cell Carcinoma of the Oral Cavity

2014

Introduction: Squamous cell carcinoma represents about 90% of malignancies of the mouth and about 38% of the head and neck tumors. The behavior of the cancer is very aggressive, presenting early cervical metastasis and, often contralateral ranging from 0.9 to 36%. Objectives: This study aims to analyze clinical and pathological factors that may influence metastasis of squamous cell carcinoma in cervical lymph nodes and relate this occurrence in the contralateral primary tumor, with disease prognosis and the interference of this type of metastasis in the survival rate of patients with this pathology. Material and Metohds: It was conducted a retrospective study from medical records of patient…

medicine.medical_specialtyPathologyOral Medicine and Pathologybusiness.industryResearchCancerRetrospective cohort studyOdontologíamedicine.disease:CIENCIAS MÉDICAS [UNESCO]Primary tumorCiencias de la saludMetastasismedicine.anatomical_structureCervical lymph nodesUNESCO::CIENCIAS MÉDICASMedicineRadiologyLymphStage (cooking)businessGeneral DentistrySurvival rate
researchProduct

PReS-FINAL-2088: Risk of severe adverse events in juvenile idiopathic arthritis and pediatric-onset inflammatory bowel disease, treated with anti-tnf…

2013

Introduction: Severe adverse events have been described in children affected by Juvenile Idiopathic Arthritis (JIA) and Inflammatory Bowel Disease (IBD) treated with anti-tnf drugs. Objectives: To define the risk of severe adverse events in patients with JIA and IBD treated with anti-tnf drugs. Methods: This is a retrospective cohort study. All patients with JIA and IBD attending the "IRCCS Burlo Garofolo" of Trieste from 2000 to 2012 were enrolled. They were divided into 2 groups on the basis of the presence or absence of anti-tnf exposure. Severe adverse events were considered the followings: a) infections needing anti-tnf permanent suspension and/or hospitalization; b) autoimmune disease…

medicine.medical_specialtyPathologyPediatric onsetArthritismacromolecular substancesInflammatory bowel diseaseanti-TNF pediatric rheumatology arthritis adverse events inflammatory bowel diseaseRheumatologyinflammatory bowel diseaseInternal medicinemedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child HealthPediatric rheumatologyAdverse effectbusiness.industryanti-TNFmedicine.diseaseadverse eventsdigestive system diseasesRheumatologypediatric rheumatologyarthritisPediatrics Perinatology and Child HealthPoster PresentationTumor necrosis factor alphabusiness
researchProduct

Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor…

2003

Chondrosarcomas are malignant cartilage-forming tumors that represent the second most common malignant solid tumor of bone. These biologically poorly understood neoplasms vary considerably in clinical presentation and biologic behavior. Chemotherapy and radiation therapy are generally ineffective. Here we describe the establishment and characterization of a new human chondrosarcoma cell line named ch-2879, and we compare the cell line with its tumor of origin. The cell line was established from a recurrent grade 3 chondrosarcoma of the chest wall and characterized by growth kinetics and morphologic studies. Immunocytochemistry and RT-PCR were performed to examine the expression of cartilage…

medicine.medical_specialtyPathologyPopulationCell Culture TechniquesChondrosarcomaBone NeoplasmsChromosomal translocationVimentinPathology and Forensic MedicineCyclin D1Tumor Cells CulturedmedicineHumanseducationMolecular BiologyMetaphaseChromosome Aberrationseducation.field_of_studymedicine.diagnostic_testbiologyCytogeneticsKaryotypeCell BiologyFlow Cytometrymedicine.diseaseMicroscopy ElectronKaryotypingbiology.proteinCancer researchChondrosarcomaFluorescence in situ hybridizationLaboratory Investigation
researchProduct

Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.

2013

Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthr…

medicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAlpha (ethology)DiseaseGastroenterologyProinflammatory cytokinePathogenesisRisk FactorsInternal medicineInternal MedicinemedicineHumansHeart FailureInflammationCrohn's diseaseTumor Necrosis Factor-alphabusiness.industrymedicine.diseaseHeart failureRheumatoid arthritishearth failure.biologicsChronic DiseaseTumor necrosis factor alphabusiness
researchProduct

Study of Cellular DIMA Content by Flow Cytometry in Primary Bladder Carcinomas

1992

A prospective study of cellular DNA content by flow cytometry was performed on a nonconsecutive series of 67 patients undergoing diagnostic and/or therapeutic transurethral resection for primary urothelial bladder carcinoma. DNA-aneuploidy was present in 82% of the cases (55/67), while multiclonality was found in 45% of the DNA-aneuploid cases (25/55). DNA-ploidy was much more strictly correlated with histological grading (p less than 0.005) than with papillary or non-papillary growth pattern (p less than 0.05) or T staging (p less than 0.05). Of 26 patients with a minimum follow-up of 24 months, 100% (6/6) of cases with DNA-diploid neoplasias showed no signs of disease relapse, versus 10% …

medicine.medical_specialtyPathologyUrinary bladdermedicine.diagnostic_testbusiness.industryUrologyCytogeneticsmedicine.diseaseFlow cytometrymedicine.anatomical_structureCellular dnaMonoclonalmedicineCarcinomaProspective cohort studybusinessGrading (tumors)European Urology
researchProduct

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

1995

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent. Int J Urol 1995;2:100-1…

medicine.medical_specialtyPathologyUrologyUrologyPhases of clinical researchlaw.inventionlawRecurrencemedicineHumansPapillary transitional cell carcinomaCarcinoma Transitional Cellbusiness.industryTumor Necrosis Factor-alphaRecombinant ProteinRecombinant ProteinsRecombinant Tumor Necrosis Factor-AlphaIntravesical treatmentAdministration IntravesicalTolerabilityUrinary Bladder NeoplasmsToxicityRecombinant DNATumor necrosis factor alphabusinessHuman
researchProduct

Role of radiology in central hemangioma of jaws

2010

Central hemangioma, a bone destructive lesion, is a benign tumor. Hemangiomas of jaws are rare entity and produ- ces many different radiographic images. Radiographic differential diagnosis includes osteosarcoma, fibrous dysplasia, central giant cell granuloma, ameloblastoma, odontogenic myxoma, multiple myeloma, dentigerous cyst and aneurysmal bone cyst. Since it involves proliferation of blood vessels so aspiration or biopsy of such lesions can lead to severe hemorrhage which can turn out to be lethal. We stress on the importance of radiology in the timely diagnosis of such lesions which can prevent the disaster not only to the patient but also to oral surgeon in legal and professional asp…

medicine.medical_specialtyPathologybusiness.industryFibrous dysplasiafood and beveragesOdontologíaAneurysmal bone cystmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOdontogenic myxomaBenign tumorDentigerous cystHemangiomaUNESCO::CIENCIAS MÉDICASmedicineRadiologybusinessAmeloblastomaGeneral DentistryCentral giant-cell granuloma
researchProduct

Teratoma with a malignant somatic component in pediatric patients: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience

2010

Background Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse. Procedure The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC. Clinical files and pathology specimens were reviewed. Results The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1). Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosar…

medicine.medical_specialtyPathologybusiness.industryMalignant peripheral nerve sheath tumorHematologyLiposarcomamedicine.diseaseOncologyPediatrics Perinatology and Child HealthmedicineCarcinomaRadiologyGerm cell tumorsTeratomaSarcomaChondrosarcomaRhabdomyosarcomabusinessPediatric Blood & Cancer
researchProduct

Unicystic ameloblastoma in 3 year old paediatric patient: a rare entity

2013

Unicystic ameloblastoma (UA) is a benign epithelial odontogenic tumor of the jaws that commonly occurs in 2nd and 3rd decade of life. In fact, this entity is rare in children under 12 years of age. It is characterised as a distinct variant of ameloblastoma, exhibiting a less aggressive behaviour and a lower rate of recurrence than solid conventional ameloblastoma. There are very few reported cases of UA occurring in children below five years of age. The purpose of this case report is to describe a case of UA involving the crown of an unerupted maxillary second premolar in a 3 year old girl. The pathogenesis, clinical appearance, radiographic presentation, histological findings and managemen…

medicine.medical_specialtyPathologybusiness.industryUnicystic AmeloblastomaRare entityOdontogenic tumorCase ReportClinical appearanceOdontologíamedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludClinical and Experimental DentistryUNESCO::CIENCIAS MÉDICASMedicinePresentation (obstetrics)businessAmeloblastomaGeneral DentistryMaxillary second premolarPaediatric patients
researchProduct